文献速递糖尿病

PBMCs中SIRT1与miR-34a-5p表达作为2型糖尿病伴认知障碍患者的潜在生物标志物

SIRT1 and miR-34a-5p Expression in PBMCs as Potential Biomarkers for Patients With Type 2 Diabetes With Cognitive Impairments.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

研究纳入374名受试者(AD、T2DM-CI、T2DM-nCI及健康对照),检测PBMCs线粒体功能、mtDNA含量、SIRT1及miRNAs表达。T2DM-CI患者PBMCs中mtDNA含量和SIRT1 mRNA表达低于T2DM-nCI,miR-34a-5p表达高于T2DM-nCI(均P<.05);SIRT1联合miR-34a-5p区分T2DM-CI与T2DM-nCI的AUC为0.793(灵敏度80.01%,特异度78.46%)。

要点

  • T2DM-CI患者PBMCs中mtDNA含量和SIRT1 mRNA表达低于T2DM-nCI,miR-34a-5p表达高于T2DM-nCI(均P<.05)。
  • SIRT1联合miR-34a-5p区分T2DM-CI与T2DM-nCI的AUC为0.793,灵敏度80.01%,特异度78.46%。
  • T2DM-CI中miR-34a-5p表达与高血糖相关。

核心结论

  • T2DM-CI患者外周存在线粒体改变,PBMCs中SIRT1联合miR-34a-5p在识别T2DM-CI方面表现良好,可能是有前景的生物标志物。

研究设计与样本

  • 研究纳入374名受试者,包括AD、T2DM-CI、T2DM-nCI和健康对照,检测PBMCs线粒体功能、mtDNA含量、SIRT1及选定miRNAs表达。

主要发现

  • AD患者PBMCs线粒体功能较对照显著改变(均P<.05),T2DM-CI患者未见此改变。
  • T2DM-CI患者PBMCs中mtDNA含量和SIRT1 mRNA表达低于T2DM-nCI,miR-34a-5p表达高于T2DM-nCI(均P<.05)。
  • SIRT1联合miR-34a-5p区分T2DM-CI与T2DM-nCI的AUC为0.793,灵敏度80.01%,特异度78.46%。
  • 相关分析显示T2DM-CI中miR-34a-5p表达与高血糖相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with type 2 diabetes mellitus (T2DM) are at significantly increased risk of Alzheimer disease (AD). However, no biomarkers are available for early identification of patients with T2DM with cognitive impairment (T2DM-CI). Mitochondrial dysfunction is linked to AD. Silent Information Regulator 1 (SIRT1), which is responsible for regulating mitochondrial biogenesis, and its related miRNAs were also altered in AD. OBJECTIVE: This study aimed to determine whether mitochondrial function in peripheral blood mononuclear cells (PBMCs) of patients with T2DM-CI was altered and if these alterations could be used as biomarkers. METHODS: A total of 374 subjects were enrolled, including AD, T2DM-CI, T2DM-nCI (T2DM without cognitive impairment), and healthy controls. The mitochondrial function was determined using a commercial assay kit. The mitochondrial DNA (mtDNA) content, the expression of SIRT1, and selected miRNAs in PBMCs were measured by quantitative polymerase chain reaction. The correlations and diagnostic accuracy were assessed using the Spearman correlation coefficient or receiver operating characteristics analysis, respectively. RESULTS: We found significant changes in mitochondrial function in PBMCs of patients with AD compared with controls (all P < .05), which were not found in T2DM-CI. However, mtDNA content and SIRT1 mRNA expression were lower in PBMCs of patients with T2DM-CI, while miR-34a-5p expression was higher than in patients with T2DM-nCI (all P < .05). A combination of SIRT1 and miR-34a-5p demonstrated excellent discrimination between T2DM-CI and T2DM-nCI (area under the curve = 0.793; sensitivity: 80.01%; specificity: 78.46%). Furthermore, correlation analysis revealed a link between miR-34a-5p expression and hyperglycemia in T2DM-CI. CONCLUSION: Our findings revealed that there was an alteration of mitochondria at the peripheral level in patients with T2DM-CI. SIRT1 combined with miR-34a-5p in PBMCs performed well in identifying patients with T2DM-CI and may be a promising biomarker.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Liu X, Zhao Z, Chen D, et al. SIRT1 and miR-34a-5p Expression in PBMCs as Potential Biomarkers for Patients With Type 2 Diabetes With Cognitive Impairments. J Clin Endocrinol Metab. 2024. PMID: 37758217. doi:10.1210/clinem/dgad562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。